menu
    • menu

    Company profile for Ketabon

    NEW Drugs in Dev: 1
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Ketabon, a collaboration between HMNC Brain Health and Develco Pharma, is focused on the development of an extended-release oral formulation of ketamine for the treatment of Treatment-Resistant Depression (TRD). The key objective is to create a formulation that offers prolonged release and minimal dissociative side effects. This innovative approach has the potential to enhance the risk profile and convenience for patients, d...
    Ketabon, a collaboration between HMNC Brain Health and Develco Pharma, is focused on the development of an extended-release oral formulation of ketamine for the treatment of Treatment-Resistant Depression (TRD). The key objective is to create a formulation that offers prolonged release and minimal dissociative side effects. This innovative approach has the potential to enhance the risk profile and convenience for patients, distinguishing it from existing intravenous and intranasal ketamine therapies. Ketabon is dedicated to advancing a novel and improved treatment option for individuals dealing with Treatment-Resistant Depression.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    KetabonGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Wilhelm-Wagenfeld-Straße 20 D-80807 München
    Telephone
    Telephone
    +49 15123146187
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ketabon.health/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof

    Cosmoprof

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ketabon Reveals Oral Ketamine (KET01) Antidepressant Effects
    Ketabon Reveals Oral Ketamine (KET01) Antidepressant Effects

    15 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/15/3167316/0/en/Ketabon-Presents-New-Data-Showing-Antidepressant-Effects-of-Oral-Ketamine-KET01-Are-Independent-of-Dissociation.html

    GLOBENEWSWIRE
    15 Oct 2025
    Share Share
    Ketabon To Present At-Home Ketamine Therapy At ECNP 2024
    Ketabon To Present At-Home Ketamine Therapy At ECNP 2024

    18 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/18/2948187/0/en/Ketabon-To-Present-Advancements-In-At-Home-Ketamine-Therapy-For-Treatment-Resistant-Depression-At-ECNP-Congress-2024.html

    GLOBENEWSWIRE
    18 Sep 2024
    Share Share
    Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home
    Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home

    14 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/14/2724556/0/en/Ketabon-GmbH-Reports-Top-Line-Results-from-Phase-2-Trial-of-Take-at-Home-Oral-Ketamine-Option-for-Treatment-Resistant-Depression.html

    GLOBENEWSWIRE
    14 Aug 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search